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Abstract
Summary The probability of initiating with anti-osteoporosis
therapy increased from 7 % in 2000 to 46 % in 2010. This
improvement was greater for patients over the age of 75 years.
Men, those overweight, having dementia or exposed to anti-
psychotics, sedatives/hypnotics or opioid analgesics were sig-
nificantly less likely to receive anti-osteoporosis drugs.
Introduction The objective of this study was to examine
trends and determinants of anti-osteoporosis drug prescribing
after hip fracture in the UK between 2000 and 2010.
Methods Data were extracted from the UK Clinical Practice
Research Datalink for patients ≥50 years who had a first hip
fracture between 2000 and 2010 and who did not currently
(≤6 months prior) receive anti-osteoporosis drugs
(bisphosphonates, strontium ranelate, parathyroid hormone,
calcitonin and raloxifene) (n=27,542). The cumulative inci-
dence probability of being prescribed anti-osteoporosis drugs
within 1 year after hip fracture was estimated by Kaplan-
Meier life-table analyses. Determinants for treatment initiation
were estimated by Cox proportional hazards models.
Results The probability of being prescribed any anti-
osteoporosis drug after hip fracture increased from 7 % in
2000 to 46% in 2010. This trend was more marked in patients
≥75 years. The increase in prescribing of anti-osteoporosis
drugs was complemented by a similar increase in vitamin
D/calcium provision. Cumulative incidence of receiving
anti-osteoporosis therapy was greater at any given point in
time in women (8 % in 2000, 51 % in 2010) compared to
men (4 % in 2000, 34 % in 2010). In addition to male gender,
multivariable Cox regression identified reduced likelihood of
receiving anti-osteoporosis drugs for those being overweight,
having dementia and exposed to psychotropic drugs (antipsy-
chotics, sedatives/hypnotics) or opioid analgesics.
Conclusion Although the prescribing of anti-osteoporosis
drugs after hip fracture has increased substantially since
2000, the overall rate remained inadequate, particularly in
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men. With the continuing increase in the absolute number of
hip fractures, further research should be made into the barriers
to optimise osteoporosis management.
Keywords Anti-osteoporotic drugs . Bisphosphonate .
Osteoporosis . Osteoporotic fracture
Introduction
Osteoporosis is a growing public health issue affecting an
estimated 2.8 million people within the UK [1]. Osteoporosis
results in fragility fractures, the most serious of which are hip
fractures. In the last decade, absolute numbers of hospital
admissions for hip fractures have increased by 15.5 %, despite
age- and sex-standardised rates remaining stable since 2003
[2]. A history of hip fracture increases the risk of future frac-
ture 3.2 times when compared to patients without a hip frac-
ture [3], and this risk is greatest in the first year and remains
elevated for at least 5 years [4, 5].
Hence, post-fracture treatment with anti-osteoporosis drugs
is important to prevent the occurrence of new fragility frac-
tures. Over the decade 2000–2010, the therapies available for
treatment of osteoporosis have changed markedly. Initially,
hormone replacement therapy (HRT) was the first-line osteo-
porosis treatment [6]. However, since the Woman’s Health
Initiative trial in 2002 demonstrated that the risk of coronary
heart disease, pulmonary embolism, stroke and breast cancer
was greater than the benefits conferred by this therapy, its use
has been limited to the short-term relief of menopausal symp-
toms [7]. Since then, bisphosphonates have been the mainstay
of treatment for osteoporosis. Bisphosphonates have been
shown to reduce the risk of hip fractures by 30–50 % and
vertebral fractures by 30–70 % [8]. From 2005 onwards, the
National Institute for Health and Clinical Excellence (NICE)
has also endorsed the use of raloxifene, teriparatide, strontium
ranelate and calcitonin (although now withdrawn) for second-
ary fracture prevention. Despite these readily available, effec-
tive treatments, a care gap in pharmacological prevention of
subsequent fractures has been documented worldwide [9–11].
Given the ageing population and therefore the increasing
number of hip fractures, it is important to know the trend in
prescribing practice for anti-osteoporosis drugs and to identify
patients at risk of not receiving these drugs. Fortunately, sev-
eral, but not all, studies have shown an improvement in anti-
osteoporosis drug prescribing between the late 1990s and the
first half of the twenty-first century, where few studies have
investigated prescribing practices over more recent years
[12–20] or have concerned concomitant prescribing of anti-
osteoporosis drugs with vitamin D and/or calcium supple-
ments [21–23]. The latter is important since clinical trials
demonstrating efficacy of anti-osteoporosis drugs were all
conducted among participants receiving adequate levels of
calcium and vitamin D. In 2010, a national clinical audit in
the UK showed that as many as 40 % of all hip fracture pa-
tients did not receive any form of anti-osteoporosis drug treat-
ment within 12 weeks [24]. Numbers for concomitant or sole-
ly prescribing of anti-osteoporosis drugs and calcium/vitamin
D were not provided, and prescribing practices were not pre-
sented beyond age and gender while other patient characteris-
tics may influence prescribing practice as well. Individual data
linking drug prescribing and patient characteristics (e.g. pre-
vious fractures, lifestyle variables, co-morbidities, poly-phar-
macy) would greatly assist in determining which patient
groups are at increased risk of not receiving anti-
osteoporosis drug treatment after hip fracture.
Therefore, the objective of the present study was to inves-
tigate the trends in prescribing of anti-osteoporosis drugs and
co-prescribing with vitamin D/calcium supplements in hip
fracture patients, who were not currently in receipt of anti-
osteoporosis drugs, within a primary care setting in the UK
between 2000 and 2010. Additionally, we aimed to examine
which patient characteristics influenced the initialisation of
anti-osteoporosis drug treatment.
Methods
Source population
The population was sourced from the Clinical Practice Re-
searchDatalink (CPRD) which contains anonymised electron-
ic health records from 625 primary care practices from across
the UK representing around 8 % of the population. The re-
cords include details of all diagnoses and prescriptions issued
by NHS general practitioners, specialist referrals, hospital ad-
missions and lifestyle variables (e.g. body mass index,
smoking status) for community-dwelling, but not institution-
alized, patients.
Study population
The study population comprised patients aged ≥50 years who
suffered an incident hip fracture between 1 January 2000 and
31 December 2010 and who did not receive a prescription for
any anti-osteoporosis drug (bisphosphonates, calcitonin,
strontium ranelate, raloxifene, parathyroid hormone ana-
logues [teriparatide]) in the 6 months prior to the index hip
fracture. A 6-month period was chosen since previous studies
have shown that the vast majority of patients who stop with
anti-osteoporosis treatment restart their treatment within
6 months [25] and is also in line with previous studies [16].
To ensure that the hip fracture was the first hip fracture, pa-
tients with a record of non-specified fractures any time prior to
the index hip fracture date were excluded. Approval for this
study was given by the Independent Scientific Advisory
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Committee for MHRA Database Research (protocol number
13_113, amendment 2).
Outcome
The outcome of interest was a prescription for an anti-
osteoporosis drug in the year following hip fracture. This
was defined as a prescription for either: bisphosphonates
(alendronic acid, risedronic acid, ibandronic acid, etidronic
acid and zoledronic acid), calcitonin, strontium ranelate, ral-
oxifene or parathyroid hormone analogues (teriparatide) based
upon the NICE guidelines for secondary osteoporosis treat-
ment [26]. Additionally, prescribing trends for calcium/
vitamin D (separately and in combination with anti-
osteoporosis drugs) and hormone replacement therapy
(HRT) were described. Patients were followed from the date
of index hip fracture until the date of the first prescription or
censoring, whichever came first. Patients were censored upon
death, exit from the database or end of the follow-up period
(365 days after the index hip fracture, 31 December 2011 at
the latest).
Determinants
Factors identified as potential determinants for anti-
osteoporosis drug prescribing were largely based on risk fac-
tors for osteoporosis or fracture: age; sex; smoking status
(non-smoker, ex-smoker, current smoker, missing); the most
recent record of body mass index ([BMI]; <18, 18–25,
>25 kg/m2, missing); history of major fracture (clinical verte-
brae, forearm, humerus); falls (3–12 months before); a history
of secondary osteoporosis in accordance with the FRAX def-
inition [27]; inflammatory bowel disease (Crohn’s disease and
ulcerative colitis); rheumatoid arthritis; Parkinson’s disease;
cerebrovascular disease; ischaemic heart disease; and the use
in the 6 months prior of corticosteroids, antipsychotics, anti-
depressants, opioid analgesics stronger than tramadol, anti-
convulsants and benzodiazepines and other sedatives/
hypnotics or calcium/vitamin D. In addition to these, a history
of dementia or malignant neoplasms and the total number of
different prescriptions (poly-pharmacy) in the 6 months prior
to hip fracture may also influence prescribing practice. Indi-
cation for osteoporosis treatment is historically based on bone
mineral density (BMD); however, this data is not routinely
available within the CPRD and so could not be included in
this analysis.
Statistical analysis
Sex-specific descriptive characteristics were calculated at base-
line. Kaplan-Meier life-table analyses were used to estimate the
cumulative incidence probability for receiving a prescription
for anti-osteoporosis drugs within 1 year of hip fracture. The
analysis was done separately for each calendar year and strati-
fied by age categories (50–74, 75–84, ≥85 years), region (En-
gland, Scotland, Wales and Northern Ireland) and sex. We also
examined prescribing trends over time for the individual drug
classes, type of bisphosphonate, and for calcium/vitamin D
both separately and in combination with anti-osteoporosis
drugs. For the latter analysis, patients were required to not have
received both anti-osteoporosis drugs and calcium/vitamin D in
the 6 months before hip fracture.
Univariate and multivariate Cox proportional hazard models
were used to identify which factors (including the year of index
hip fracture) were determinants of anti-osteoporosis drug initi-
ation. Since for some of the covariates’ (BMI, smoking status)
missing data were present, multiple imputation was used to
create five imputed datasets. Analyses were performed sepa-
rately for the five imputed datasets, and hazard ratios (HRs)
were pooled using the MIANALYZE procedure. All analyses
were carried out using SAS 9.2 (SAS, Cary NC, USA).
Results
Trends in anti-osteoporosis drug prescribing
Over the 10-year period, 30,516 patients aged 50 years or
older suffered a hip fracture. Of these, 2974 (9.7 %) had re-
ceived at least one prescription for anti-osteoporosis drugs in
the 6 months prior to the index fracture. Table 1 shows the
characteristics of the study population. The median age (inter-
quartile range) was 83 (76–88) and 79 years (71–85) for fe-
males and males, respectively.
After index hip fracture, 6684 patients received some form
of anti-osteoporosis therapy, of which 94 % of the prescrip-
tions were for bisphosphonates. The mean time to receiving a
prescription was 88 days (SD80). The remaining patients, 20,
858 (68 %), had no record of receiving osteoporosis medica-
tion in either the 6 months prior or in the year following hip
fracture.
During the study period, there was a steady rise in anti-
osteoporosis drug prescribing following a hip fracture. Among
patients who were not currently on treatment, the probability of
receiving an anti-osteoporosis drug increased from 7.4 % in
2000 to 45.5 % in 2010. Cumulative incidence of receiving
anti-osteoporosis drugs was greater at any given point in time
in women compared tomen. The proportion of women that was
prescribed an anti-osteoporosis drug in 2000 was 8.2 % and
increased to 51.3 % in 2010. These numbers were 4.1 and
33.6 % for men, respectively. By 2010, a female hip fracture
patient was 1.5 times more likely to be prescribed an anti-
osteoporosis drug when compared to males (Fig. 1a).
Figure 1b demonstrates that this trend also differed between
age categories, with a more pronounced trend for patients aged
75 years and older than for those under the age of 75 years,
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particularly after 2005 where the prescribing rates continued to
increase for the older population but stabilised for patients un-
der the age of 75 years. Figure 1c shows that there was a general
improvement in anti-osteoporosis prescribing for all four UK
regions (England, Scotland, Wales and Northern Ireland), but
levels of prescribing varied considerable across these regions.
From 2008, theses rates diverged with an increase in Northern
Ireland and a decrease in Scotland.
Evaluation of the medication classes individually demon-
strated a substantial rise in the prescribing of bisphosphonates
within 1 year after hip fracture (Fig. 2a). Figure 2b shows the
trend in the prescribing of bisphosphonates, stratified by the
type of bisphosphonate. Alendronic acid was the most fre-
quently prescribed bisphosphonate followed by risedronic ac-
id, and after 2006, this disparity became markedly greater.
Zoledronic acid was not included in the figure as numbers
Table 1 Baseline characteristics
of hip fracture patients who were
not in receipt of anti-osteoporosis
drugs
a Imputed values were used for
regression models
b As defined by FRAX; anorexia
nervosa, coeliac disease, diabetes
mellitus (type 1), hypogonadism,
o s t e og en e s i s impe r f e c t a ,
osteomalacia, l iver disease
( c i r r h o s i s , h e p a t i t i s a n d
neop lasms) , ma lnu t r i t ion ,
malabsorption and premature
menopause
Characteristic Male (n=7051) Female (n=20,491) Total (n=27,542)
Age category, n, %
50–74 2348 33.3 4177 20.4 6525 23.7
75–84 2801 39.7 7860 38.3 10,661 38.7
85+ 1902 27.0 8454 41.3 10,356 37.6
BMI category, n, %
<18 kg/m2 590 8.4 2547 12.4 3137 11.4
18–25 kg/m2 2390 33.9 6384 31.2 8774 31.9
>25 kg/m2 2470 35.0 5703 27.8 8173 29.7
Missinga 1601 22.7 5857 28.6 7458 27.1
Smoking category, n, %
Non-smoker 2393 33.9 10,595 51.7 12,988 47.2
Ex-smoker 2068 29.3 3010 14.7 5078 18.4
Current smoker 1879 26.7 4058 19.8 5937 21.6
Missinga 711 10.1 2828 13.8 3539 12.8
Disease history, n, %
≥1 fall (3–12 months prior hip fracture) 494 7.0 1792 8.7 2286 8.3
History of major fracture 689 9.8 4152 20.3 4841 17.5
Secondary osteoporosisb 511 7.2 1023 5.0 1534 5.6
Inflammatory bowel disease 95 1.3 224 1.1 319 1.2
Rheumatoid arthritis 160 2.3 652 3.2 812 2.9
Parkinson’s disease 368 5.2 579 2.8 947 3.4
Dementia 679 9.6 2747 13.4 3426 12.4
Cerebrovascular disease 1545 21.9 3444 16.8 4989 18.1
Ischaemic heart disease 1683 23.9 3624 17.7 5307 19.3
Malignant neoplasms 1296 18.4 2818 13.8 4114 14.9
Drugs history (6 months prior), n, %
Antipsychotics 445 6.3 1667 8.1 2112 7.7
Antidepressants 1323 18.8 4945 24.1 6268 22.8
Anti-epileptics 403 5.7 810 4.0 1213 4.4
Corticosteroids 1249 17.7 2907 14.2 4156 15.1
Opioid analgesics 1248 17.7 3933 19.2 5181 18.8
Sedatives and hypnotics 1004 14.2 4074 19.9 5078 18.4
Calcium/vitamin D 360 5.1 2069 10.1 2429 8.8
Hormone replacement therapy 3 0 274 1.3 277 1.0
Number of different prescriptions, n, %
<5 different prescriptions 2110 29.9 6285 30.7 8395 30.5
5–9 different prescriptions 2300 32.6 7214 35.2 9514 34.5
10–14 different
prescriptions
1490 21.1 4198 20.5 5688 20.7
>14 different prescriptions 1151 16.3 2794 13.6 3945 14.3
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were too low (n=2). Finally, from Fig. 3, it can be seen that
there has been a dramatic increase in the combined prescribing
of anti-osteoporosis drugs together with vitamin D/calcium
supplementation.
Determinants of anti-osteoporosis drug prescribing
Multivariable Cox regression identified increased likelihood
of being prescribed an anti-osteoporosis drug after hip fracture
for increasing calendar year, female sex (adj. HR=1.74, 95 %
confidence interval (CI) 1.64–1.86), rheumatoid arthritis
(HR=1.26, 95% CI 1.11–1.42) and the presence of secondary
osteoporosis (HR=1.13, 95 % CI 1.03–1.26), corticosteroid
use and a history of major osteoporotic fracture. When com-
pared to patients younger than 60 years, patients between the
ages of 60–90 years were significantly more likely to receive
osteoporosis therapy. Conversely, having dementia, a BMI
>25 kg/m2 or using antipsychotics, sedatives/hypnotics, or
opioid analgesics were negatively associated with the initia-
tion of osteoporosis therapy (Table 2).
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Meier method), stratified by sex
(a), age categories (b) and region
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Discussion
The last decade has seen a striking change in prescribing prac-
tices for anti-osteoporosis drugs following a hip fracture. The
probability of initiating anti-osteoporotic treatment has in-
creased dramatically, particularly for patients over the age of
75 years. It was also apparent that the initiation of anti-
osteoporosis drugs was paired with the initiation of calcium/
vitamin D supplementation. However, this encouraging trend
slowed down from 2006 onwards. Ultimately, the overall pre-
scribing rate has remained inadequate with just over 50 % of
hip fracture patients not receiving any anti-osteoporosis drug
in 2010. The factors which were associated with reduced
likelihood of receiving anti-osteoporosis drug therapy were
male gender, being overweight, having dementia or exposed
to certain psychotropic drugs (antipsychotics, sedatives/hyp-
notics) or opioid analgesics.
Our findings of a steady increase in the prescribing of anti-
osteoporosis drugs up until 2005 are consistent with most
studies performed in other countries [15–19] and form an
extension to the study performed on the former version of
the CPRD (GPRD) for the period 1991–2005 by Watson
et al. [20]. The pattern of anti-osteoporosis drug prescribing
may be reflective of changes in bisphosphonate formulation,
advice from various committees and changes to NHS guide-
lines. As from 2005, there was a pronounced difference in
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Fig. 2 Trends in anti-
osteoporosis drug prescribing
after hip fracture (by Kaplan-
Meier method), stratified by drug
class (a) and type of
bisphosphonate (b)
0
10
20
30
40
50
Tr
ea
tm
en
t w
ith
in
 o
ne
 y
ea
r (
%
)
Year of index hip fracture
Fig. 3 Trends in anti-
osteoporosis drug and calcium/
vitamin D prescribing
individually or combined
(by Kaplan-Meier method)
1924 Osteoporos Int (2015) 26:1919–1928
prescribing of anti-osteoporosis medications between patients
under and over 75 years. This is most likely a consequence of
the NICE Technology Appraisal 87 published in 2005 [28],
which advocated the use of anti-osteoporosis therapies with-
out the need for prior dual energy X-ray absorptiometry
(DXA) scanning for women over the age of 75 years who
had already suffered a hip fracture. This, however, does not
explain why the prescribing rate plateaued for those <75 years.
We have no clear explanation for this phenomenon, but it may
be partly related to the actual proportion of hip fractures that
was attributable to osteoporotic BMD. This proportion has
been reported to a range between 28 and 64 %, depending
on age and sex [29, 30]. Since DXA-derived diagnosis of
osteoporosis has been the cornerstone for indicating anti-
osteoporosis drug therapy, an increase in DXA referrals may
not necessarily have resulted in a further increase in anti-
osteoporosis drug prescribing as osteoporosis may subse-
quently not have been diagnosed for many younger hip frac-
ture patients. Furthermore, the cost of anti-osteoporotic drugs
has been reduced further since the release of generic forms of
alendronic acid in August 2005. Subsequently, NICE guid-
ance (TA161) endorsed alendronic acid as the first-line thera-
py. This resulted in the stabilisation in the prescribing of
risedronic acid in 2005 whose use then went into decline
[26]. The majority of anti-osteoporosis drug prescribing was
paired with the prescribing of vitamin D/calcium supplements
which is in line with clinical guidelines. Another UK study
that was conducted in 2006 among nine general practitioner
practices showed that 34 % of patients were co-prescribed
calcium and/or vitamin D with anti-osteoporosis drugs [23].
This coincides well with our results with a cumulative inci-
dence probability of 39 % in 2006. Unfortunately, there was a
considerable number of patients who only received vitamin D/
calcium supplementation.
Inline with the results by Wang et al. [31], we found a
slowing down in the increasing prescribing trend from 2006
onwards, while an Australian study showed a decline between
2007 and 2010 [32]. Reasons for the stagnation or even decline
in anti-osteoporosis drug prescribing may coincide with revised
labelling of bisphosphonates for risk of osteonecrosis of the jaw
in 2005 and reports for increased risk of atypical femoral frac-
tures and atrial fibrillation, with increasing publicity in the years
thereafter. A US study showed a decline in use of anti-
osteoporosis drugs after hip fracture from 2002 onwards
(40.2 % in 2002 to 20.5 % in 2011) [12]. Together with the
possible influence of safety issue reports, this could have been
attributed to a fragmented health care system with a lack of, or
insufficient, communication between emergency/orthopaedic
departments and outpatient care for follow-up osteoporosis as-
sessment. A service model to bridge this gap, the Fracture Liai-
son Service (FLS), now exists for over a decade in the UK
which has proven to reduce the care gap for secondary fracture
prevention [33]. However, this care model has been developed
Table 2 Cox proportional hazard ratios (95 % CI) for anti-osteoporosis
drug initiation within 12 months of incident hip fracture.
Characteristic Age-sex-adjusted
HR (95 % CI)
Fully adjusted
HR (95 % CI)
Index year of hip fracture
2001 vs. 2000 1.33 (1.05–1.68) 1.33 (1.06–1.68)
2002 vs. 2000 1.88 (1.51–2.33) 1.88 (1.51–2.34)
2003 vs. 2000 2.60 (2.12–3.18) 2.61 (2.13–3.20)
2004 vs. 2000 3.54 (2.91–4.32) 3.57 (2.93–4.36)
2005 vs. 2000 5.46 (4.51–6.62) 5.49 (4.53–6.66)
2006 vs. 2000 6.79 (5.61–8.21) 6.83 (5.65–8.27)
2007 vs. 2000 7.15 (5.91–8.64) 7.19 (5.95–8.70)
2008 vs. 2000 8.50 (7.04–10.3) 8.72 (7.21–10.5)
2009 vs. 2000 8.50 (7.02–10.3) 8.63 (7.13–10.5)
2010 vs. 2000 9.77 (8.08–11.8) 9.87 (8.15–11.9)
Age (years)
60–69 vs. 50–59 1.10 (0.96–1.26) 1.18 (1.03–1.35)
70–80 vs. 50–59 1.21 (1.08–1.37) 1.48 (1.30–1.67)
80–89 vs. 50–59 1.19 (1.05–1.33) 1.43 (1.73–1.61)
≥90 vs. 50–59 0.89 (0.78–1.02) 1.04 (0.91–1.20)
Gender
Female vs. male 1.52 (1.43–1.62) 1.74 (1.64–1.86)
BMI category (kg/m2)
<18 vs. 18–25 0.93 (0.83–1.04) 0.95 (0.84–1.07)
>25 vs. 18–25 0.87 (0.83–0.92) 0.86 (0.82–0.91)
Smoking category
Ex-smoker vs. non-smoker 1.16 (1.09–1.24) 0.98 (0.92–1.05)
Current smoker vs. non-smoker 0.84 (0.79–0.90) 1.00 (0.93–1.07)
Disease historya (%)
≥1 fall (3–12 months prior ) 0.94 (0.86–1.04) 0.91 (0.83–1.00)
History of major fracture 1.13 (1.07–1.21) 1.12 (1.05–1.19)
Secondary osteoporosisb 1.23 (1.12–1.36) 1.13 (1.03–1.26)
Inflammatory bowel disease 1.16 (0.94–1.43) 1.03 (0.83–1.27)
Rheumatoid arthritis 1.31 (1.16–1.48) 1.26 (1.11–1.42)
Parkinson’s disease 0.94 (0.82–1.08) 1.03 (0.90–1.18)
Dementia 0.66 (0.61–0.72) 0.65 (0.59–0.71)
Cerebrovascular disease 0.96 (0.90–1.02) 0.99 (0.93–1.06)
Ischemic heart disease 1.01 (0.95–1.07) 0.98 (0.92–1.04)
Malignant neoplasms 1.03 (0.96–1.10) 0.92 (0.87–1.00)
Drugs historya (in 6 month prior to hip fracture) (%)
Antipsychotics 0.53 (0.47–0.60) 0.66 (0.58–0.74)
Antidepressants 0.95 (0.89–1.00) 0.98 (0.92–1.04)
Anti-epileptics 1.02 (0.90–1.14) 0.96 (0.85–1.08)
Corticosteroids 1.22 (1.14–1.30) 1.16 (1.08–1.25)
Opioid analgesics 0.86 (0.80–0.91) 0.93 (0.86–0.99)
Sedatives and hypnotics 0.83 (0.77–0.88) 0.92 (0.86–0.99)
Calcium/vitamin D 1.21 (1.12–1.31) 1.04 (0.96–1.13)
Number of prescriptions 1.01 (1.01–1.01) 1.00 (0.99–1.01)
HR hazard ratio, CI confidence interval
a Reference category is no history of disease or exposure to a drug
bAnorexia nervosa, coeliac disease, diabetes mellitus I, hypogonadism,
osteogenesis imperfecta, osteomalacia, liver disease (cirrhosis, hepatitis
and neoplasms), malnutrition, malabsorption, and premature menopause
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in 27 % of UK NHS Hospital Trusts prior to 2006, which has
barely increased to 29 % by 2009. This is in line with the
flattening in prescribing rates for this period.
Few studies have examined which factors lead to the initi-
ation of anti-osteoporosis drugs after hip fracture. Many of the
factors which increase the risk of fracture were also significant
determinants for initiation of anti-osteoporosis drug therapy.
Hence, female gender, increasing age (except for very old
age), a history of major osteoporotic fracture, rheumatoid ar-
thritis, secondary osteoporosis and the use of corticosteroids
all increased the likelihood of receiving osteoporosis treat-
ment which is in line with previous studies [12, 34–37]. Con-
versely, patients who were suffering from mental illness (i.e.
using antipsychotics, sedatives and hypnotics or having de-
mentia) or patients who were overweight or used opioid anal-
gesics were less likely to receive osteoporosis therapy. Other
factors which have been associated with the initiation of anti-
osteoporosis drug treatment are patients’ self-perception of
osteoporosis risk [34] and their appraisal for their treatment
need [38], but these could not be identified in our data. The
fact that an increasing number of prescriptions was not in-
versely associated with the instigation of osteoporosis therapy
was unexpected given the findings of Duyvendak et al. [39]
who found that poly-pharmacy was a barrier to osteoporosis
treatment in long-term corticosteroid users. The study of Sol-
omon et al. [12] even found an increased likelihood of being
prescribed anti-osteoporosis drugs with increasing number of
prescriptions which was also conducted among hip fracture
patients. Consistent with other findings is the observation that
male hip fracture patients were less likely to be prescribed
anti-osteoporosis drugs than female patients [12, 16, 40].
The difference in prescribing patterns between men and wom-
en is likely partly due to osteoporosis primarily being consid-
ered a health problem of older women [41, 42], rather than of
men; consequently, men often have poor knowledge of the
condition and therefore do not consider themselves as suscep-
tible [43, 44] and hence would not consider asking their GP
for treatment. Furthermore, the number of clinical trials exam-
ining the effect of bisphosphonates on fracture reduction in
men is limited, where the majority of trials used change in
bone mineral density (BMD) as the primary end point [45,
46]. The few trials into the effects of bisphosphonate use on
fracture reduction in men and lack of clinical guidance for
anti-osteoporosis drug prescribing for men may explain why
GPs do not habitually provide bisphosphonate treatment to
men. However, seeing as the bisphosphonate has a similar
effect on bone turnover and density in both men and women,
the difference in prescribing habits is likely unjustified.
We studied a large community-dwelling population repre-
sentative of the UK as a whole. However, there are several
limitations that should be considered in the interpretation of
our results. By studying hip fracture patients, we have as-
sumed that all of our study population was eligible for anti-
osteoporosis medication according to a confirmed diagnosis
of osteoporosis, while this may not necessarily have been the
case. BMD measurements are not routinely available in the
CPRD which limits our interpretation as to the eligibility for
treatment. Additionally, it is possible that some fractures were
pathological or due to trauma. Furthermore, we have only
considered initial prescription rates and did not include repeat
prescriptions. Therefore, we cannot make any comments re-
garding adherence with treatment. It is well known that a large
proportion of patients do not adhere to their treatment regi-
men, although the exact reasons for this phenomenon remain
poorly understood [47]. Zoledronic acid as well as PTH ana-
logues (teriparatide) and denosumab are not fully captured in
CPRD records as this database only includes prescriptions
issued by general practitioners and not specialists. This may
have resulted in an underestimate of anti-osteoporosis therapy
initiation. However, denosumab became available in the UK
at the end of the study period (2010), and although we cannot
directly estimate the magnitude of this limitation for PTH
analogues and zoledronic acid, indirect evidence from other
countries has shown that the utilisation of these drugs
remained limited until the year 2010 [12, 32]. Furthermore,
NICE guidance places teriparatide under restrictive conditions
for the secondary prevention of fragility fractures. Similarly,
data for non-prescription over-the-counter vitamin D or calci-
um were not available in our database, which may have re-
sulted in an underestimate of use of these drugs. Finally, the
generalisability of this study is limited to free-living individ-
uals as it excluded those whowere institutionalized. Just under
10 % of the patients transferred out of the database, most
likely to nursing homes where prescribing practices could
differ.
In conclusion, our study has shown that although the pre-
scribing rate for anti-osteoporosis medications has increased
substantially since 2000, the overall rate in 2010 was still
markedly inadequate. This was particularly so in men, where
the prescribing of anti-osteoporosis drugs was notably less
than that observed in women at any given point in time. Other
patient characteristics that were associated with decreased
likelihood of receiving anti-osteoporosis drugs were being
overweight, having dementia and exposed to antipsychotics,
sedatives/hypnotics or opioid analgesics. Increase in the pre-
scribing of anti-osteoporosis medications may be facilitated
by recent major advances in risk assessment, such as the
FRAX calculator [48], linked to treatment thresholds, as ex-
emplified by the UK NOGG Guidelines [49]. There is much
work to promote secondary fracture prevention services [50],
notably by the current International Osteoporosis Foundation
Capture the Fracture initiative [51]. With the absolute number
of hip fractures expected to increase inexorably across the
world over coming decades, our findings clearly demonstrate
the acute need for such activity and for the generally increased
awareness of osteoporosis and prevention of fragility fracture.
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